Olmesartan Tad (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartan Tad, is a angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and helps lower blood pressure in adult patients. GNH USA supplies Olmesartan Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Tad is an angiotensin II receptor blocker indicated for conditions affecting the renin‑angiotensin system.

- Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. - Heart failure: used as part of combination therapy to improve symptoms and outcomes. - Diabetic nephropathy: helps slow progression of kidney damage associated with diabetes. - Post‑myocardial infarction: contributes to blood‑pressure control in patients after a heart attack. - Chronic kidney disease: assists in managing elevated blood pressure in CKD patients. - High‑risk vascular risk patients: aids in overall vascular risk reduction.

Olmesartan Tad may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Cough

Serious or Rare Side Effects: - Angio‑angry   - Hyper‑hyper   - Severe hypotension - Acute kidney injury - Liver enzyme elevation - Anaphylaxis  

Olmesartan Tad should be used with caution in specific clinical situations.

- Renal impairment: adjust dosing and monitor kidney function. - Hepatic impairment: use with caution; limited data in severe liver disease. - Electrolyte disturbances: monitor serum potassium and sodium levels. - Pregnancy   - Breastfeeding   - Store at ambient  :  keep   

The     

---

     t   t \\